Precision Cancer Therapeutics, 2022

Precision Cancer Therapeutics, 2022

Despite advances in cancer treatment, cancer continues to affect about 18.1 million people annually, generating a significant loss of life, financial burden and overall strain on the health industry. Worldwide between 35 and 40 million people are living with cancer and nearly 10 million people lose the battle annually. The most common cancers affecting the world population include lung, breast, colon/rectum, stomach, liver, prostate, cervical, esophageal, and bladder. Cancer deaths occur in about 50% of people who develop cancer in developed countries; this is in contrast to 80% death rate in cancer patients in underdeveloped countries.

The demand for more effective and tolerable cancer treatments has led to the development of novel therapeutic agents that specifically target the malignant cells. Today, advanced precision cancer therapies are available, and more are being developed each year. Although there are some older precision therapies on the market, the industry is now expanding the use of these treatments to better treat cancer victims. Precision treatments are less invasive and less damaging to the body, and they promise improved outcomes in many cases.

This report Precision Cancer Therapeutics, 2022 specifically focuses on five leading segments of precision therapies:

  • Monoclonal antibodies
  • Kinase inhibitors
  • Angiogenesis inhibitors
  • Proteasome inhibitors
  • CAR-T therapies
  • Other precision therapies
Additionally, smaller areas of precision therapies are covered including mTOR inhibitors, PI3K inhibitors, PARP inhibitors, apoptosis inhibitors, histone deacetylase inhibitors, CDK inhibitors, hedgehog signaling pathway inhibitors and several others.

Scope and Methodology

Kalorama Information has watched the cancer treatment market evolve over the past two decades and evaluated the impact new technologies are making on the market. Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress.

This report covers precision cancer therapies that do at least one of the following:
  • Block or turn off chemical signals that tell the cancer cell to grow and divide
  • Change proteins within the cancer cells so the cells die
  • Stop making new blood vessels to feed the cancer cells
  • Trigger the immune system to kill the cancer cells
  • Carry toxins to the cancer cells to kill them, but not normal cells
The report includes statistical information for cancers by type on a global level. Specifically, cancers where there are current products available or are in development and/or have significant incidence/mortality rates are profiled. The market segments provide an overview of disease epidemiology, leading product sales, market estimates and forecasts, and competitive summary of leading providers. The report also includes a list of Phase 3 precision therapies in development. Throughout the report, several market indicators, trends and barriers are discussed.


CHAPTER 1: EXECUTIVE SUMMARY
OVERVIEW
SCOPE AND METHODOLOGY
MARKET OVERVIEW AND ANALYSIS
Figure 1-1: Global Precision Cancer Therapeutic Market Size and Forecast, 2017-2027 ($millions)
CHAPTER 2: INTRODUCTION
GLOBAL CANCER BURDEN
Figure 2-1: Incidence of Cancer by Type, 2020
Figure 2-2: Distribution of Cancer Incidence by Type, 2020
INTRODUCTION TO CANCER
Biochemistry of Cancer Cells
CAUSES OF CANCER GROWTH MAY SHED LIGHT ON TREATMENT
Environmental Factors, DNA, RNA
Table 2-1: Virus Association with Human Cancer
Cellular Oncogenes
Tumor Suppressor Genes
CANCER TREATMENT APPROACHES
Table 2-2: Characteristics of Cancer Treatment Approaches (chemotherapy, hormone therapy, Precision therapy)
WHAT IS PRECISION CANCER THERAPY?
TRENDS IN RESEARCH AND DEVELOPMENT OF PRECISION CANCER THERAPEUTICS
MONOCLONAL ANTIBODIES: THE LEADING AREA OF CANCER PRECISION THERAPY
CHAPTER 3: PRECISION CANCER THERAPIES: MONOCLONAL ANTIBODIES
MONOCLONAL ANTIBODY OVERVIEW
MARKET OUTLOOK
Figure 3-1: Cancer Monoclonal Antibody Market, 2017-2027 ($ millions)
PRINCIPAL PRODUCTS
Table 3-1: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
Figure 3-2: Top 10 Cancer Indicated Monoclonal Antibodies, 2021 and 2022 Sales (millions $)
Avastin (bevacizumab)
Blincyto (blinatuomab)
Darzalex (daratumumab)
Erbitux (cetuximab)
Herceptin (trastuzumab)
Kadcyla (ado-trastuzumab emtansine)
Keytruda (pembrolizumab)
Libtayo (cemiplimab-rwlc)
Opdivo (nivolumab)
Padcev (enfortumab vedotin-jfv)
Perjeta (pertuzumab)
Rituxan (rituximab)
Sarclisa (isatuximab)
Tivdak (tisolumab vedotin-tftv)
Tecentriq (atezolizumab)
Vectibix (panitumumab)
Xgeva (denosumab)
Yervoy (ipilimumab)
Table 3-2: Selected Monoclonal Antibodies in Cancer Therapy
LATE-STAGE MONOCLONAL ANTIBODIES DEVELOPMENT
Table 3-3: Selected Late-Stage Monoclonal Antibodies in Phase 3 Development
MARKET BREAKDOWN OF MONOCLONAL ANTIBODIES
Cancer Monoclonal Antibody Market by Target
Table 3-4: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
Figure 3-3: Cancer Monoclonal Antibody Market by Target, 2022 and Forecast 2027 ($ millions)
Figure 3-4: Cancer Monoclonal Antibody Market Distribution by Target, 2022 (%)
Figure 3-5: Cancer Monoclonal Antibody Market Distribution by Target, 2027 (%)
Cancer Monoclonal Antibody Market by Type
Figure 3-6: Development of the mAb Cancer Treatment Market, 2010-2027 ($ millions)
Table 3-5: Cancer Treatment mAb Market by Type, 2022-2027 ($ millions)
Figure 3-7: Monoclonal Antibody Market by Cancer Type, 2022 and 2027 ($ millions)
Figure 3-8: Monoclonal Antibody Market, Distribution by Cancer Type, 2022 (%)
Figure 3-9: Monoclonal Antibody Market Distribution by Indication, 2027 (%)
REGIONAL MARKET SUMMARY
Figure: 3-10: Cancer Monoclonal Antibody Market Summary by Geographic Region, 2022 and 2027 ($ millions)
COMPETITOR SUMMARY
Merck & Co.
Genentech/Roche
Bristol-Myers Squibb
Janssen Biotech/J&J
Amgen
AstraZeneca
EMD Serono
Table 3-6: Cancer Monoclonal Antibody Competitor Market Share - Top Seven, 2022 ($ millions)
CHAPTER 4: PRECISION CANCER THERAPIES: KINASE INHIBITORS
KINASE INHIBITOR OVERVIEW
MARKET OUTLOOK
Figure 4-1: Kinase Inhibitor Market, 2022-2027: CAGR 8.8% ($ millions)
PRINCIPAL PRODUCTS
Table 4-1: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)
Figure 4-2: Top 10 Cancer Indicated Kinase Inhibitors, 2021 and Forecast 2022 Sales (millions $)
Alecensa (alectinib)
Alunbrig (brigatinib)
Imbruvica (ibrutinib)
Inlyta (axitinib)
Sprycel (dasatinib)
Tasigna (nilotinib)
Tagrisso (osimertinib)
Gleevec (imatinib)
Mekinist+Tafinlar (trametinib + dabrafenib)
Sutent (sunitinib)
Jakafi/Jakavi (ruxolitinib)
Nexavar (sorafenib)
Tukysa (tucatinib)
Votrient (pazopanib)
Table 4-2: Kinase Inhibitors in Cancer Therapy
LATE-STAGE KINASE INHIBITORS DEVELOPMENT
Table 4-3: Selected Phase 3 Kinase Inhibitors in Development
MARKET BREAKDOWN OF KINASE INHIBITORS
Cancer Kinase Inhibitor Market by Target
Table 4-4: Cancer Kinase Inhibitor Market by Target, 2022 and Forecast 2027 ($ millions)
Figure 4-3: Cancer Kinase Inhibitor Market by Target, 2022 and 2027 ($ millions)
Figure 4-4: Kinase Inhibitor Market Distribution by Target, 2022 (%)
Figure 4-5: Kinase Inhibitor Market Distribution by Target, 2027 (%)
Cancer Kinase Inhibitor Market by Type
Figure 4-6: Development of the Kinase Inhibitor Cancer Treatment Market, 2010-2027 ($ millions)
Table 4-5: Cancer Treatment Kinase Inhibitor Market by Type, 2022-2027 ($ millions)
Figure 4-7: Kinase Inhibitor Market by Cancer Indication, 2022 and 2027 ($ millions)
Figure 4-8: Kinase Inhibitor Market Distribution by Cancer Indication, 2022 (%)
Figure 4-9: Kinase Inhibitor Market Distribution by Cancer Indication, 2027 (%)
REGIONAL MARKET SUMMARY
Figure: 4-10: Cancer Kinase Inhibitor Market Summary by Geographic Region, 2022 and 2027 ($ millions)
COMPETITOR SUMMARY
Novartis
AstraZeneca
AbbVie
Johnson & Johnson
Pfizer
Bristol-Myers Squibb
Roche/Genentech
Table 4-6: Cancer Kinase Inhibitor Competitor Market Share, 2022 ($ millions)
CHAPTER 5: PRECISION CANCER THERAPIES: ANGIOGENESIS INHIBITORS
ANGIOGENESIS INHIBITOR OVERVIEW
MARKET OUTLOOK
Figure 5-1: Angiogenesis Inhibitor Market, 2017-2027 ($ millions)
PRINCIPAL PRODUCTS
Pomalyst/Imnovid (pomalidomide)
Revlimid (lenalidomide)
Thalomid (thalidomide)
Zaltrap (ziv-aflibercept)
Table 5-1: Angiogenesis Inhibitors in Cancer Therapy
LATE-STAGE ANGIOGENESIS INHIBITOR PHASE 3 DEVELOPMENT
Table 5-2: Selected Phase 3 Angiogenesis Inhibitor Development
REGIONAL MARKET SUMMARY
Figure: 5-2: Cancer Angiogenesis Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
COMPETITOR SUMMARY
CHAPTER 6: PRECISION CANCER THERAPIES: CAR-T THERAPIES
CAR-T OVERVIEW
MANUFACTURING PROCESS FOR CAR-T
Leukapheresis
Activation
Transduction
Expansion
REGULATORY DEVELOPMENTS
MARKET OUTLOOK
Figure 6-1: CAR-T Market, 2017-2027 ($ millions)
PRINCIPAL PRODUCTS
Abecma
Breyanzi
Carvykti
Kymriah
Tecartus
Yescarta
LATE-STAGE CAR-T THERAPIES DEVELOPMENT
Table 6-1: Phase III Development  CAR-T Therapies, Select Projects
REGIONAL MARKET SUMMARY
Figure: 6-2: Cancer CAR-T Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
COMPETITOR SUMMARY
CHAPTER 7: PRECISION CANCER THERAPIES: PROTEASOME INHIBITORS
PROTEASOME INHIBITOR OVERVIEW
MARKET OUTLOOK
Figure 7-1: Proteasome Inhibitor Market, 2022-2027 ($ millions)
PRINCIPAL PRODUCTS
Kyprolis (carfilzomib)
Ninlaro (ixazomib)
Velcade (bortezomib)
Table 7-1: Proteasome Inhibitors in Cancer Therapy
REGIONAL MARKET SUMMARY
Figure 7-2: Cancer Proteasome Inhibitor Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
COMPETITOR SUMMARY
Takeda
Amgen
Table 7-2: Cancer Proteasome Inhibitor Competitor Market Share, 2022 ($ millions)
CHAPTER 8: PRECISION CANCER THERAPIES: OTHER PRECISION THERAPIES
OTHER PRECISION THERAPIES OVERVIEW
MARKET OUTLOOK
Figure 8-1: Other Precision Therapies Market, 2017-2027 ($ millions)
PRINCIPAL PRODUCTS
mTOR Inhibitor  Afinitor (everolimus)
mTOR Inhibitor  Torisel (temsirolimus)
PI3K Inhibitor  Zydelig
PARP Inhibitor  Lynparza
PARP Inhibitor  Zejula
Apoptosis Inducer  Venclexta
CDK Inhibitors - Ibrance (palbociclib)
CDK Inhibitors - Kisqali (ribociclib)
Table 8-1: Other Precision Cancer Therapies
LATE-STAGE OTHER THERAPIES DEVELOPMENT
Table 8-2: Select Phase 3 Other Therapies Development
REGIONAL MARKET SUMMARY
Figure: 8-2: Other Precision Therapies Market Summary by Geographic Region, Estimated 2022 and 2027 ($ millions)
CHAPTER 9: MARKET SUMMARY
MARKET INFLUENCES
Global Demographics
Table 9-1: Global Population, through 2050 (population in millions)
Aging Population
Figure 9-1: Global Population Trends, Total Population vs. Age 65+ Population, 2000-2050
Cancer: A Growing Economic Burden
Cost Containment
Table 9-2: The Cost of Monoclonal Antibodies (2020-2021)
Reimbursement Landscape: A Deciding Factor for Success
The Biosimilar Movement
REGIONAL MARKET OVERVIEW
Table 9-3: Precision Cancer Therapeutics Market Summary by Geographical Region, 2022-2027 ($ millions)
UNITED STATES AND CANADA
Table 9-4: Precision Cancer Therapeutics Market Summary for U.S. and Canada, 2022-2027 ($ millions)
Figure 9-2: Precision Cancer Therapeutics for U.S. and Canada, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 %
EMEA
Table 9-5: Precision Cancer Therapeutics Market Summary for EMEA, 2022-2027 ($ millions)
Figure 9-3: Precision Cancer Therapeutics for EMEA, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
ASIA PACIFIC
Table 9-6: Precision Cancer Therapeutics Market Summary for Asia Pacific, 2022-2027 ($ millions)
Figure 9-4: Precision Cancer Therapeutics for Asia Pacific, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
LATIN AMERICA
Table 9-7: Precision Cancer Therapeutics Market Summary for Latin America, 2022-2027 ($ millions)
Figure 9-5: Precision Cancer Therapeutics for Latin America, Distribution by Therapy Type (monoclonal antibodies, kinase inhibitors, angiogenesis inhibitors, proteasome inhibitors, CAR-T, other Precision therapies), 2022 (%)
CHAPTER 10: MARKET PARTICIPANTS
TOP 15 OVERVIEW
Table 10-1: Global Market Participants for Precision Cancer Therapeutics, Top 15 Companies, 2022 ($ in millions)
Figure 10-1: Global Market Share for Precision Cancer Therapeutics, 2022 %
Figure 10-2: Growth in Precision Cancer Therapeutics by Company 2010 vs. 2022 ($ in millions)
Figure 10-3: Growth Trend by Company, 2010-2022 CAGR: Precision Cancer Therapeutics
ABBVIE, INC.
Table 10-2: AbbVie Corporate Summary
Company Summary
AMGEN
Table 10-3: Amgen Corporate Summary
Company Summary
ASTELLAS PHARMA U.S., INC
Table 10-4: Astellas Corporate Summary
Company Summary
ASTRAZENECA PLC
Table 10-5: AstraZeneca Corporate Summary
Company Summary
BAYER AG
Table 10-6: Bayer Corporate Summary
Company Summary
BRISTOL-MYERS SQUIBB COMPANY
Table 10-7: Bristol-Myers Squibb Corporate Summary
Company Summary
CLOVIS ONCOLOGY, INC.
Table 10-8: Clovis Oncology Corporate Summary
Company Summary
DENDREON PHARMACEUTICALS LLC
Table 10-9: Dendreon Corporate Summary
Company Summary
ELI LILLY & COMPANY
Table 10-10: Eli Lilly Corporate Summary
Company Summary
EMD SERONO, INC. (MERCK KGAA)
Table 10-11: EMD Serono Corporate Summary
Company Summary
EISAI CO., LTD.
Table 10-12: Eisai Corporate Summary
Company Summary
EXELIXIS, INC.
Table 10-13: Exelixis Corporate Summary
Company Summary
GILEAD SCIENCES, INC.
Table 10-14: Gilead Sciences Corporate Summary
Company Summary
GLAXOSMITHKLINE
Table 10-15: GSK Corporate Summary
Company Summary
JOHNSON & JOHNSON
Table 10-16: Johnson & Johnson Corporate Summary
Company Summary
MERCK & CO., INC.
Table 10-17: Merck & Co. Corporate Summary
Company Summary
NOVARTIS AG
Table 10-18: Novartis Corporate Summary
Company Summary
OTSUKA HOLDINGS CO., LTD.
Table 10-19: Otsuka Corporate Summary
Company Summary
PFIZER, INC.
Table 10-20: Pfizer Corporate Summary
Company Summary
PUMA BIOTECHNOLOGY, INC.
Table 10-21: Puma Biotechnology Corporate Summary
Company Summary
ROCHE (F. HOFFMAN-LA ROCHE, LTD.)
Table 10-22: Roche Corporate Summary
Company Summary
SANOFI/GENZYME
Table 10-23: Sanofi/Genzyme Corporate Summary
Company Summary
SEAGEN INC.
Table 10-24: Seagen Corporate Summary
Company Summary
TAKEDA ONCOLOGY - MILLENNIUM PHARMACEUTICALS
Table 10-25: Takeda Oncology Corporate Summary
Company Summary

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings